伊诺加群
中文名称 | 伊诺加群 |
---|---|
中文同义词 | 伊诺加群;化合物 T11659;INOGATRAN (H-314-27) |
英文名称 | inogatran |
英文同义词 | inogatran;Glycine, N-[(1R)-2-[(2S)-2-[[[3-[(aminoiminomethyl)amino]propyl]amino]carbonyl]-1-piperidinyl]-1-(cyclohexylmethyl)-2-oxoethyl]-;H-314-27;Inogatran (H-314-27) |
CAS号 | 155415-08-0 |
分子式 | C21H38N6O4 |
分子量 | 438.56 |
EINECS号 | |
相关类别 | |
Mol文件 | 155415-08-0.mol |
结构式 |
伊诺加群 性质
密度 | 1.36±0.1 g/cm3(Predicted) |
---|---|
储存条件 | Store at -20°C |
溶解度 | 溶于二甲基亚砜 |
酸度系数(pKa) | 2.16±0.10(Predicted) |
Inogatran (H-314-27; 0.075, 0.25, 0.75 mg/kg, i.v.) results in dose-dependent increases in activated partial thromboplastin time (aPTT), thrombin time (TT), and prothrombin time (PT) in a canine electrolytic injury model of venous thrombosis.
Inogatran dose-dependently inhibits thrombus formation, which is measured as an increase in time to occlusion (TTO) and a decrease in thrombus weight. Inogatran also improves vena caval blood flow and reduces the overall incidence of thrombotic occlusion in a rat model.